GlobeNewswire Inc | Feb 12, 2021 04:18PM EST

February 12, 2021

AUSTIN, Texas, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Aspira Womens Health, Inc. (Nasdaq: AWH), a bioanalytical-based womens health company, today announced management will participate and present in the 2021 BTIG Virtual MedTech, Digital Health, Life Science and Diagnostic Tools Conference taking place on February 17-19. Details for the event are below:

BTIG MedTech, Digital Health, Life Science and Diagnostic Tools ConferencePresentation:Date: Thursday, February 18, 2021Time: 9:30 am Eastern TimeWebcast: https://wsw.com/webcast/btig3/awh/1583008

About Aspira Womens Health Inc.Aspira Womens Health, Inc. (formerly known as Vermillion Inc.,Nasdaq:VRML) is transforming womens health with the discovery, development, and commercialization of innovative testing options and bio-analytical solutions that help physicians assess risk, optimize patient management and improve gynecologic health outcomes for women.ASPIRA is particularly focused on closing the ethnic disparity gap in ovarian cancer risk assessment and developing solutions for pelvic diseases such as pelvic mass risk assessment and endometriosis.OVA1plus includes our FDA-cleared products, OVA1and OVERAto detect risk of ovarian malignancy in women with adnexal masses. ASPIRA GenetiXTMtesting offers both targeted and comprehensive genetic testing options with a gynecologic focus.With over 10 years of expertise in ovarian cancer risk assessment, ASPIRA is delivering a portfolio of pelvic mass products over a patients lifetime with our cutting-edge research. The next generation of products in development are OVASightTMand EndoCheckTM.Visit our website for more information at www.aspirawh.com.

Investor Relations Contact:Ashley R. Robinson LifeSci Advisors, LLC Tel 617-430-7577Arr@lifesciadvisors.com